Novo Asks US Regulators to Restrict Compounded Weight-Loss Drugs

Novo Nordisk A/S took aim at copycat versions of its blockbuster weight-loss and diabetes drugs by telling US regulators that Wegovy and Ozempic should be added to a list of drugs that can only be made in a closely monitored manufacturing setting.

• The Denmark-based company’s law firm asked the Food and Drug Administration to add semaglutide, the key ingredient in the two drugs, to “lists of drug products that present demonstrable difficulties for compounding,” according to a filing released Tuesday
• Novo asked that the FDA “convene and consult” an advisory committee on compounding to discuss adding semaglutide products to the ...